Abstract: The FDA Critical Path Initiative: A Perspective of the First Four Years (2010 AAAS Annual Meeting (18-22 February 2010))

1137 The FDA Critical Path Initiative: A Perspective of the First Four Years

Friday, February 19, 2010: 10:50 AM

Room 17B (San Diego Convention Center)

Gail Cassell , Eli Lilly and Company, Indianapolis, IN

See more of: Evaluating and Funding Translational Research
See more of: Translational and Personalized Medicine
See more of: Seminars

<< Previous Abstract | Next Abstract >>